October 20, 2020 11:22 AM EDT
News Briefing

News brief­ing: Mer­ck preps FDA pitch af­ter adding more da­ta on V114; Bris­tol My­ers, Ex­elix­is get quick re­view for can­cer com­bo

ENDPOINTS

Mer­ck has new da­ta out from two Phase III tri­als on its pneu­mo­coc­cal con­ju­gate vac­cine can­di­date cov­er­ing 15 dif­fer­ent serotypes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

A service from the Financial Times